Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence

American Journal on Addictions

Volumn 18, Issue 5, 2009, Pages 393-401

  Adler, Lenard ^a   Wilens, Timothy ^b,c   Zhang, Shuyu ^d   Durell, Todd ^e   Walker, Daniel ^d   Schuh, Leslie ^d   Jin, Ling ^d   Feldman, Peter ^d   Trzepacz, Paula ^d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e Lilly USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATOMOXETINE; BILIRUBIN; PLACEBO;

ABNORMAL DREAMING; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLISM; ALKALINE PHOSPHATASE BLOOD LEVEL; APPETITE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; KIDNEY DISEASE; LIVER FUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NOSE CONGESTION; PARESTHESIA; PATIENT COMPLIANCE; POST HOC ANALYSIS; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ALCOHOLISM; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; VITAL SIGNS;

EID: 71049158026     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490903077663     Document Type: Article

References (41)

1. Riccio CA, Wolfe M, Davis B, Romine C, George C, Lee D. Attention deficit hyperactivity disorder: manifestation in adulthood. Arch Clin Neuropsychol. 2005;20:249-269
2. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36:21-29 (Pubitemid 27024224)
3. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652-1658
4. Molina BS, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112:497-507
5. Arias AJ, Gelertner J, Chan G, et al. Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav. 2008;33:1199-1207
6. Wilens TE, Biederman J,Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185:475-482
7. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162:1621-1627
8. King VL, Brooner RK, Kidorf MS, Stoller KB, Mirsky AF. Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment. J Nerv Ment Dis. 1999;187:487-495
9. Schubiner H. Substance abuse in patients with attention-deficit hyperactivity disorder: therapeutic implications. CNS Drugs. 2005;19:643-655
10. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict. 1998;7:156-163
11. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120
12. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96:145-154
13. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67:149-156
14. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30:319-323
15. CarlsonA, Lindqvist M. Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmac. 1973;25:377-440
16. Corrodi H, Fuxe K, Hokfelt T. The effect of ethanol on the activity of central catecholamine neurons in the rat brain. J Pharm Pharmac. 1966;18:821-823
17. Rossetti ZL, Longu G, Mercuro G, Hmaidan Y, Gessa GL. Biphasic effect of ethanol on noradrenaline release in the frontal cortex of awake rats. Alcohol Alcohol. 1992;27:477-480
18. Aston-Jones G, Foote SL, Bloom FE. Low doses of ethanol disrupt sensory responses of brain noradrenergic neurons. Nature. 1982;296:857-860
19. Verbanck P, Seutin V, Dresse A, et al. Electrophysiological effects of ethanol on monoaminergic neurons: an in vivo and in vitro study. Alcohol Clin Exp Res. 1990;14:728-735 (Pubitemid 20354997)
20. Banerjee SP, Sharma VK, Khanna JM. Alterations in beta-adrenergic receptor binding during ethanol withdrawal. Nature. 1978;276:407-409
21. Arango V, Underwood MD, Mann JJ. Fewer pigmented neurons in the locus coeruleus of uncomplicated alcoholics. Brain Res. 1994;650:1-8
22. Adler LA, Spencer TJ, Levine LR, et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord. 2008;11:720-727
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edition, text revision.Washington, DC: American Psychiatric Association; 2000
24. Adler L, Cohen J. Diagnosis and evaluation of adults with ADHD. In: Spencer T, ed. Psychiatric Clinics of North America. Philadelphia, PA: Saunders Press; 2004:187-201
25. Sobel LC, Sobel MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, eds. Measuring alcohol consumption: Psychosocial and biochemical methods. Totowa, NH: Humana Press; 2006:41-72
26. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV TR axis I disorders, research edition, patient version, SCID I/P. New York: Biometrics Research, New York State Psychiatric Institute; 2002
27. HamiltonM.Arating scale for depression. JNeurolNeurosurg Psychiatry. 1960;23:56-62
28. HamiltonM.Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296
29. HamiltonM. The assessment of anxiety states by rating. Br JMed Psychol. 1959;32:50-55
30. Sarkar S, Watts S, Ohashi Y, et al. Bridging data between two ethnic populations. A new application of matched case-control methodology. Drug Info J. 2002;36:349-356
31. World Medical Association. Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects. As adopted by the 18th General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd General Assembly, Edinburgh, Scotland, October 2000
32. Guy W. ECDEU Assessment manual for psychopharmacology, revised. Publication ADM 76-338. Bethesda, MD: United States Department of Health, Education, and Welfare; 1976:218-222
33. Conners CK. Conners' Rating Scales: Revised technical manual. North Tonawanda, NY: Multi-Health Systems, Inc.; 1997
34. Lindros KO, Stowell L, Vaananen H, et al. Uninterrupted prolonged ethanol oxidation as a main pathogenetic factor of alcoholic liver damage: evidence from a new liquid diet animal model. Liver. 1983;3:79-91
35. STRATTERATM (atomoxetine HCl) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2008
36. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 2008;31:345-354
37. Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend. 1988;52:15-25
38. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis. 2002;21:1-16
39. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2001;21:116-118
40. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebocontrolled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10:286-294
41. Wilens T, Prince J, Murphy K, et al. Bupropion SR treatment study in adults with ADHD and substance abuse: preliminary findings. Scientific Proceedings of the 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, October 23-28, 2001, pp. 151-152. [Abs Nr P40]